According to GlobalData, the TAVR market was worth $7.0bn in 2025 and is projected to reach $13.8bn in 2035 at a CAGR of 7.1% ...
Medtronic (NYSE:MDT) today announced three-year results from the SMART trial comparing its Evolut heart valve to Edwards' ...
Edwards Lifesciences remains a high-quality business with a wide economic moat , but the stock is still overvalued. Click ...
Born in the 8-bit era, raised by the 16-bit era, and perfected by the 32-bit era, Cory's roots grew from the likes Sonic the Hedgehog and Mega Man to the world of Resident Evil and Castlevania. Owning ...
The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional ...
There are still some kinks to be ironed out, including risks of hemolysis and valve thrombosis, to put things on par with ...
BostonSci secures rights to acquire MiRus' SIEGEL TAVR system with $1.5B equity stake and potential buyout, marking its 3rd ...
Born in the 8-bit era, raised by the 16-bit era, and perfected by the 32-bit era, Cory's roots grew from the likes Sonic the Hedgehog and Mega Man to the world of Resident Evil and Castlevania. Owning ...
Clinical event rates were still no different with longer follow-up, but one investigator thinks an advantage will emerge in ...
EA Sports UFC 6 is the next installment of the MMA fighting franchise, and lets you step back into the Octagon as a variety ...
MedPage Today on MSN
Women-only trial supports self-expanding TAVR as the way to go
ALL WOMEN reported alongside 3-year data from SMART ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results